A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

Part of paid clinical trials in Los Alamitos, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07061288
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • KarXT — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia

Key Dates

Start date
Sep 3, 2025
Status verified
Dec 2025
Primary completion
Jun 21, 2027
Completion
Oct 15, 2027

Study Design

Enrollment
48 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Administration of KarXT

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 3 weeks ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    8559073286
  • First line of the email MUST contain the NCT# and Site#

Locations (8)

FacilityCityStateZIPSite coordinators
Collaborative Neuroscience Research, LLCLos AlamitosCalifornia90720-3118
David Walling, Site 0001
714-799-7799
Research Centers of America ( Hollywood )HollywoodFlorida33024
Edwin Gomez, Site 0005
954-990-7649
Innovative Clinical Research, Inc.Miami LakesFlorida33016
Rishi Kakar, Site 0004
786-512-4106
Atlanta Center for Medical ResearchAtlantaGeorgia30331
Elyssa Barron, Site 0008
404-881-5800
CenExel iResearch, LLCDecaturGeorgia30030
Kimball Johnson, Site 0003
312-942-5592
Uptown Research InstituteChicagoIllinois60640
John Sonnenberg, Site 0002
773-968-9868
Hassman Research Institute Marlton SiteMarltonNew Jersey08053
Elan Cohen, Site 0007
856-452-9901
Community Clinical ResearchAustinTexas78754
David Brown, Site 0006
512-323-2622

Find similar trials in Los Alamitos, CA

By condition

Related Studies